Skip to main content
SpringerLink
Log in

Biosimilars of tumour necrosis factor-α (TNF-α) inhibitors will erode $9.6 billion in brand sales

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources.Biosimilars of TNF-alpha Inhibitors Stand to Erode Over $9 Billion in Brand Sales in the U.S. and Europe by 2018. Media Release: 3 Nov 2009. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biosimilars of tumour necrosis factor-α (TNF-α) inhibitors will erode $9.6 billion in brand sales. Pharmacoecon. Outcomes News 591, 14 (2009). https://doi.org/10.2165/00151234-200905910-00040

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00040

Keywords

Search

Navigation